Walter Scott

Prof. Walter Scott


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
PMPeter R. Meyer
Peter R. Meyer
SMSuzanne E. Matsuura
Suzanne E. Matsuura
DZDianna Zonarich
Dianna Zonarich
RCRahul R. Chopra
Rahul R. Chopra
EPEric Pendarvis
Eric Pendarvis
WSWalter Scott
Walter Scott
Phosphonoformate (foscarnet) is a pyrophosphate (PPi) analogue and a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), acting through the PPibinding site on the enzyme. HIV-1 RT can unblock a chain-terminated DNA primer by phosphorolytic transfer of the terminal residue to an acceptor substrate (PPior a nucleotide such as ATP) which also interacts with the PPibinding site. Primer-unblocking activity is increased in mutants of HIV-1 that are resistant to the chain-terminating nucleoside inhibitor 3′-azido-3′-deoxythymidine (AZT). We have compared the primer-unblocking activity for HIV-1 RT containing various foscarnet resistance mutations (K65R, W88G, W88S, E89K, S117T, Q161L, M164I, and the double mutant Q161L/H208Y) alone or in combination with AZT resistance mutations. The level of primer-unblocking activity varied over a 150-fold range for these enzymes and was inversely correlated with foscarnet resistance and directly correlated with AZT resistance. Based on published crystal structures of HIV-1 RT, many of the foscarnet resistance mutations affect residues that do not make direct contact with the catalytic residues of RT, the incoming deoxynucleoside triphosphate (dNTP), or the primer-template. These mutations may confer foscarnet resistance and reduce primer unblocking by indirectly decreasing the binding and retention of foscarnet, PPi, and ATP. Alternatively, the binding position or orientation of PPi, ATP, or the primer-template may be changed in the mutant enzyme complex so that molecular interactions required for the unblocking reaction are impaired while dNTP binding and incorporation are not.

15 March 2003 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
PMPeter R. Meyer
Peter R. Meyer
JLJohan Lennerstrand
Johan Lennerstrand
SMSuzanne E. Matsuura
Suzanne E. Matsuura
BLBrendan A. Larder
Brendan A. Larder
WSWalter Scott
Walter Scott
Finger insertion mutations of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) (T69S mutations followed by various dipeptide insertions) have a multinucleoside resistance phenotype that can be explained by decreased sensitivity to deoxynucleoside triphosphate (dNTP) inhibition of the nucleotide-dependent unblocking activity of RT. We show that RTs with SG or AG (but not SS) insertions have three- to fourfold-increased unblocking activity and that all three finger insertion mutations have threefold-decreased sensitivity to dNTP inhibition. The additional presence of M41L and T215Y mutations increased unblocking activity for all three insertions, greatly reduced the sensitivity to dNTP inhibition, and resulted in defects in in vitro DNA chain elongation. The DNA chain elongation defects were partially repaired by additional mutations at positions 210, 211, and 214. These results suggest that structural communication between the regions of RT defined by these mutations plays a role in the multinucleoside resistance phenotype.

28 January 2010 in Viruses
Verified
Journal Article
Open access
PDF file
AHAntonio Acosta Hoyos
Antonio Acosta Hoyos
WSWalter Scott
Walter Scott
Nucleoside reverse transcriptase (RT) inhibitors of HIV block viral replication through the ability of HIV RT to incorporate chain-terminating nucleotide analogs during viral DNA synthesis. Once incorporated, the chain-terminating residue must be removed before DNA synthesis can continue. Removal can be accomplished by the excision activity of HIV RT, which catalyzes the transfer of the 3'-terminal residue on the blocked DNA chain to an acceptor substrate, probably ATP in most infected cells. Mutations of RT that enhance excision activity are the most common cause of resistance to 3'-azido-3'-deoxythymidine (AZT) and exhibit low-level cross-resistance to most other nucleoside RT inhibitors. The resistance to AZT is suppressed by a number of additional mutations in RT, most of which were identified because they conferred resistance to other RT inhibitors. Here we review current understanding of the biochemical mechanisms responsible for increased or decreased excision activity due to these mutations.

1 May 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ASAnthony J. Smith
Anthony J. Smith
PMPeter R. Meyer
Peter R. Meyer
DADeshratn Asthana
Deshratn Asthana
MAMargarita R. Ashman
Margarita R. Ashman
WSWalter Scott
Walter Scott
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected patients with 3′-azido-3′-deoxythymidine (AZT) selects for mutant forms of viral reverse transcriptase (RT) with increased ability to remove chain-terminating nucleotides from blocked DNA chains. We tested various cell extracts for the presence of endogenous acceptor substrates for this reaction. Cell extracts incubated with HIV-1 RT and [32P]ddAMP-terminated DNA primer/template gave rise to32P-labeled adenosine 2′,3′-dideoxyadenosine 5′,5′′′−P1,P4-tetraphosphate (Ap4ddA), ddATP, Gp4ddA, and Ap3ddA, corresponding to the transfer of [32P]ddAMP to ATP, PPi, GTP, and ADP, respectively. Incubation with [32P]AZT monophosphate (AZTMP)-terminated primer/template gave rise to the analogous32P-labeled AZT derivatives. Based on the rates of formation of the specific excision products, ATP and PPilevels were determined: ATP was present at 1.3 to 2.2 mM in H9 cells, macrophages, and unstimulated CD4+or CD8+T cells, while PPiwas present at 7 to 15 μM. Under these conditions, the ATP-dependent reaction predominated, and excision by the AZT-resistant mutant RT was more efficient than wild type RT. Activated CD4+or CD8+T cells contained 1.4 to 2.7 mM ATP and 55 to 79 μM PPi. These cellular PPiconcentrations are lower than previously reported; nonetheless, the PPi-dependent reaction predominated in extracts from activated T cells, and excision by mutant and wild-type RT occurred with similar efficiency. While PPi-dependent excision may contribute to AZT resistance in vivo, it is likely that selection of AZT-resistant mutants occurs primarily in an environment where the ATP-dependent reaction predominates.

1 May 2007 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PMPeter R. Meyer
Peter R. Meyer
WRWiriya Rutvisuttinunt
Wiriya Rutvisuttinunt
SMSuzanne E. Matsuura
Suzanne E. Matsuura
ASAntero G. So
Antero G. So
WSWalter Scott
Walter Scott

1 November 2006 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
PMPeter R. Meyer
Peter R. Meyer
ASAnthony J. Smith
Anthony J. Smith
SMSuzanne E. Matsuura
Suzanne E. Matsuura
WSWalter Scott
Walter Scott
Nucleoside reverse transcriptase inhibitors are an important class of drugs for treatment of human immunodeficiency virus type 1 (HIV-1) infection. Resistance to these drugs is often the result of mutations that increase the transfer of chain-terminating nucleotides from blocked DNA termini to a nucleoside triphosphate acceptor, resulting in the generation of an unblocked DNA chain and synthesis of a dinucleoside polyphosphate containing the chain-terminating deoxynucleoside triphosphate analogue. We have synthesized and purified several dinucleoside tetraphosphates (ddAp 4 ddA, ddCp 4 ddC, ddGp 4 ddG, ddTp 4 ddT, Ap 4 ddG, 2′(3′)- O -( N -methylanthraniloyl)-Ap 4 ddG, and AppNHppddG) and show that these compounds can serve as substrates for DNA chain elongation and termination resulting in inhibition of DNA synthesis. Thymidine analogue-resistant mutants of reverse transcriptase are up to 120-fold more sensitive to inhibition by these compounds than is wild-type enzyme. Drugs based on the dinucleoside tetraphosphate structure could delay or prevent the emergence of mutants with enhanced primer unblocking activity. In addition, such drugs could suppress the resistance phenotype of mutant HIV-1 that is present in individuals infected with resistant virus.